Skip to main content
. 2019 May 29;18(2):1500–1506. doi: 10.3892/etm.2019.7630

Figure 2.

Figure 2.

Meta-analysis of the studies evaluating the efficacy of epratuzumab. (A) BILAG-based Combined Lupus Assessment response, (B) BILAG index score and (C) Systemic Lupus Erythematosus Disease Activity Index 2000 score. SD, standard deviation; M-H, Mantel-Haenszel; BILAG, British Isles Lupus Assessment Group; CI, confidence intervals.